Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [1] Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Awan, Farrukh T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 13 - 14
  • [2] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
  • [3] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [4] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [5] Ibrutinib combined with venetoclax treatment outcome in chronic lymphocytic leukemia: A systematic review
    Sugianto, Jeremy Octavian
    Purushotama, Nyoman Bagus Satcitta Ananda
    Ontowirjo, Yudi Ali Putra
    Sutanto, Mario
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2023, 34 : S1447 - S1447
  • [6] Combined Ibrutinib and Venetoclax in Patients with Treatment-Naive High-Risk Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro N.
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2018, 132
  • [7] A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Wei, Lai
    Bhat, Seema A.
    Jones, Dan
    Seymour, Erlene K.
    Stephens, Deborah M.
    Christine, J.
    Byrd, John C.
    Woyach, Jennifer
    BLOOD, 2019, 134
  • [8] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Sasaki, Koji
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2020, 136
  • [9] Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia
    Hampel, Paul J.
    Rabe, Kari G.
    Call, Timothy G.
    Ding, Wei
    Leis, Jose F.
    Kenderian, Saad S.
    Muchtar, Eli
    Wang, Yucai
    Koehler, Amber B.
    Parrondo, Ricardo
    Schwager, Susan M.
    Shi, Min
    Braggio, Esteban
    Slager, Susan L.
    Kay, Neil E.
    Parikh, Sameer A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 239 - 244
  • [10] Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax
    Waldron, Madeline
    Winter, Allison
    Hill, Brian T.
    CLINICAL PHARMACOKINETICS, 2017, 56 (11) : 1255 - 1266
12345